{'fraction_non_alphanumeric': 0.031144781144781145, 'fraction_numerical': 0.015151515151515152, 'mean_word_length': 5.097435897435897, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effect of the raloxifene versus combined hormonal therapy on the mammary density].

OBJECTIVE
to compare in postmenopausal women with osteoporosis or osteopenia the effect of hydrochlorate of raloxifene versus hormone replacement therapy on the mammary density.


METHOD
a double blind, randomized clinical trial was conducted in 57 postmenopausal women older than 55 years with osteoporosis or osteopenia. Participants were randomly allocated in two groups: the intervention group (IG) received hydrochlorate of raloxifene and the control group (CG) received hormone replacement therapy during 6 months. A mammography to evaluate the change of the mammary density, according to the BIRADS criteria, was made before and after the treatment.


RESULTS
twenty-eight patients received hormone replacement therapy and 29 hydrochlorate of raloxifene. Eight (28.5 %) patients of the IG and one (3.0 %) of the CG showed an increased mammary density; whereas in none of IG patients and in four (13.7%) of the CG, the mammary density decreased (p = 0.01).


CONCLUSIONS
the hydrochlorate of raloxifene in postmenopausal women with osteoporosis or osteopenia does not increase the mammary density.